An immunomodulatory peptide CIGB-258 for the treatment of critical and severe COVID-19 patients

R. V. Rodríguez, M. C. Domínguez-Horta(Centro de Ingeniería Genética y Biotecnología), Marcela Granados Sánchez, Rosaura Ruiz, Antonio Luis Carballo García, Gerardo Guillén(Hunan City University), Idelsis Esquivel Moynelo(Centro de Ingeniería Genética y Biotecnología), R. S. Sánchez, Pedro Rafel Aroche de Dios, Mabel Hernández-Cedeño(Centro de Ingeniería Genética y Biotecnología), David Orlando León Pérez, G. Martínez-Donato(Centro de Ingeniería Genética y Biotecnología), Beatriz Santiesteban Licea, Lucas Rodrigues Santa Cruz, Mónica Béquet‐Romero(Centro de Ingeniería Genética y Biotecnología)

Revista cubana de medicina militar

January 1, 2020

Cited by 0

Related Papers

Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications

|International Wound Journal|2009|167

A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial

|Annals of Oncology|1998|155

Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing

|BioMed Research International|2012|153

Wound Chronicity, Impaired Immunity and Infection in Diabetic Patients

|MEDICC Review|2021|139

Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review

|Frontiers in Endocrinology|2020|134